JOHN CHARLES ARAUJO to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications JOHN CHARLES ARAUJO has written about Xenograft Model Antitumor Assays.
Connection Strength
0.146
-
Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate. 2011 Jun 01; 71(8):846-56.
Score: 0.050
-
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series. Clin Cancer Res. 2024 May 15; 30(10):2272-2285.
Score: 0.032
-
The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res. 2020 09 15; 26(18):4933-4946.
Score: 0.024
-
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014 Mar 15; 74(6):1651-60.
Score: 0.015
-
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate. 2013 Jun; 73(9):979-85.
Score: 0.014
-
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008 May 01; 68(9):3323-33.
Score: 0.010